NBIL:NASDAQGraniteShares 2x Long NBIS Daily ETF Analysis
Data as of 2026-04-19 - not real-time
$22.93
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The NBIL ETF is a high‑leverage, biotech‑focused product that has posted a solid YTD gain of 14.7% but sits on a precarious risk profile. A beta of 6.5 and a 30‑day volatility of over 200% underscore extreme price swings, while the historical max drawdown of -77.9% warns of deep downside potential. Technicals show the price at $22.93 trading just below the calculated resistance of $26.45 and above the support of $7.79, with the 20‑day SMA ($15.62) above both the 50‑day ($12.82) and 200‑day ($13.87) averages, suggesting short‑term upward bias. However, the RSI sits at 66.7 (near overbought) and the market sentiment is at an Extreme Greed level (90.21), indicating that bullish momentum may be overstretched. The fund’s expense ratio of 1.5% further erodes returns, especially given the daily reset nature of leveraged ETFs.
Given these dynamics, NBIL is best viewed as a tactical, short‑term play rather than a core holding. The combination of high leverage, sector concentration in biotechnology, and the inherent decay of daily‑reset structures makes long‑term exposure risky. Investors should monitor the proximity to resistance and the overbought RSI for potential pull‑backs, and remain cautious of liquidity constraints despite stable volume trends.
Given these dynamics, NBIL is best viewed as a tactical, short‑term play rather than a core holding. The combination of high leverage, sector concentration in biotechnology, and the inherent decay of daily‑reset structures makes long‑term exposure risky. Investors should monitor the proximity to resistance and the overbought RSI for potential pull‑backs, and remain cautious of liquidity constraints despite stable volume trends.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price approaching resistance at $26.45
- RSI near overbought levels
- Extreme market greed signaling potential pull‑back
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- High beta and volatility leading to possible decay
- Sector concentration in biotech increasing systemic risk
- Expense ratio of 1.5% diminishing net returns
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Leveraged daily reset structure unsuitable for long horizons
- Historical max drawdown of -77.9% illustrates severe downside risk
- Persistent high volatility and beta amplify long‑term uncertainty
Key Metrics & Analysis
Fund Metrics
Expense Ratio1.50%
AUM$59.7M
Inception Date2025-10-06
Avg Daily Volume1,839,240
Premium/Discount0.00%
Tracking Error0.00%
Technical Analysis
TrendNeutral
RSI66.7
Support$7.79
Resistance$26.45
MA 20$15.62
MA 50$12.82
MA 200$13.87
MACDBullish
VolumeStable
Fear & Greed Index90.21
Risk Assessment
Beta6.52
Volatility205.20%
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.